A pharmaceutical company develops a sequential testing protocol for a rare genetic disorder (prevalence 0.01%). Initial screening test has sensitivity 95% and specificity 90%. Positive results undergo confirmatory testing with sensitivity 99% and specificity 99.5%. The company claims this approach achieves PPV >80% for the final positive result. Evaluate this claim and the rationale for sequential testing in this context.
Q2
A hospital system is implementing a sepsis screening algorithm using clinical criteria with sensitivity of 92% and specificity of 75%. False positives result in unnecessary antibiotics, cultures, and ICU evaluations costing $3,000 per case. Missing true sepsis cases (false negatives) results in average increased mortality and morbidity costs of $50,000 per case. Hospital sepsis prevalence is 8%. Evaluate the optimal threshold adjustment strategy.
Q3
A 58-year-old man with chronic cough undergoes evaluation for tuberculosis. A tuberculin skin test (TST) is positive (15mm induration). TST has sensitivity of 80% and specificity of 95% in immunocompetent adults. However, he received BCG vaccination as a child in Asia. Local TB prevalence is 0.5%, but his occupational exposure increases his pre-test probability to 10%. Evaluate the most appropriate interpretation and management approach.
Q4
A research team develops a novel biomarker for early Alzheimer's disease. In their validation study of 500 patients with confirmed Alzheimer's and 500 age-matched controls, the biomarker is positive in 450 Alzheimer's patients and 50 controls. They plan to use this test in a memory clinic where 30% of patients have Alzheimer's. Analyze how the test performance will differ in the clinical setting compared to the validation study.
Q5
A 35-year-old woman presents with fatigue and is found to have a positive antinuclear antibody (ANA) test. The test has sensitivity of 95% and specificity of 85% for systemic lupus erythematosus (SLE). She has no other symptoms or physical findings suggestive of SLE. The prevalence of SLE in asymptomatic women her age is 0.1%. Analyze the significance of her positive test result.
Q6
A public health department is comparing two screening tests for colorectal cancer. Test A has sensitivity 85% and specificity 90%. Test B has sensitivity 70% and specificity 98%. The department must screen a population with 2% disease prevalence and has limited resources for colonoscopy follow-up. Analyze which test would be more appropriate for this screening program.
Q7
A 62-year-old diabetic man undergoes screening for peripheral artery disease using ankle-brachial index (ABI). His ABI is 0.85 (normal >0.90). Studies show ABI has sensitivity of 75% and specificity of 95% for detecting significant PAD. Given his diabetes and symptoms of claudication, the pre-test probability is estimated at 40%. Apply these test characteristics to determine the most appropriate next step.
Q8
A hospital implements a rapid HIV test with sensitivity of 99% and specificity of 98% in their emergency department. A 28-year-old man with no known risk factors presents after a needlestick injury and tests positive. The prevalence of HIV in the general population presenting to this ED is 0.5%. What is the approximate positive predictive value of his test result?
Q9
A 45-year-old woman undergoes screening mammography. The radiologist reports that the test has a specificity of 95%. In a population where the prevalence of breast cancer is 1%, what does this specificity value primarily tell you about the test's performance?
Q10
A new screening test for pancreatic cancer is being evaluated in a population of 1,000 patients. Of these, 100 patients have pancreatic cancer confirmed by biopsy. The screening test is positive in 90 of the patients with cancer and positive in 180 of the patients without cancer. What is the sensitivity of this screening test?
Sensitivity/Specificity US Medical PG Practice Questions and MCQs
Question 1: A pharmaceutical company develops a sequential testing protocol for a rare genetic disorder (prevalence 0.01%). Initial screening test has sensitivity 95% and specificity 90%. Positive results undergo confirmatory testing with sensitivity 99% and specificity 99.5%. The company claims this approach achieves PPV >80% for the final positive result. Evaluate this claim and the rationale for sequential testing in this context.
A. The claim is true; sequential testing increases PPV by enriching the population tested in the second step (Correct Answer)
B. The claim is false; sensitivity decreases with sequential testing, reducing PPV
C. Sequential testing is unnecessary; the first test alone achieves adequate PPV
D. The claim is false; sequential testing cannot achieve PPV >80% with such low prevalence
E. The claim is true; the high specificity of the confirmatory test ensures high PPV regardless of prevalence
Explanation: ***The claim is true; sequential testing increases PPV by enriching the population tested in the second step***
- Sequential testing works by increasing the **pre-test probability** for the second test, as the cohort being tested has already screened positive once.
- By applying a highly specific confirmatory test to this enriched group, the number of **false positives** is significantly reduced, which drastically improves the **Positive Predictive Value (PPV)**.
*The claim is false; sequential testing cannot achieve PPV >80% with such low prevalence*
- Even with a low **prevalence**, the multiplication of specificities in a sequential process can reduce the **False Positive** rate to a level where the PPV exceeds 80%.
- This line of reasoning ignores that the **denominator** of the PPV calculation (True Positives + False Positives) decreases much faster than the numerator during the second stage.
*The claim is true; the high specificity of the confirmatory test ensures high PPV regardless of prevalence*
- While high **specificity** is crucial, PPV is always dependent on the **prevalence** (pre-test probability) of the condition in the group being tested.
- The claim is true because sequential testing specifically raises that **pre-test probability**, not because prevalence is irrelevant to the calculation.
*The claim is false; sensitivity decreases with sequential testing, reducing PPV*
- It is true that **net sensitivity** decreases in sequential testing, but a decrease in sensitivity actually tends to have a negligible effect on PPV compared to specificity gains.
- **PPV** is primarily driven by the **specificity** and the prevalence in the tested population, both of which are optimized in this two-step protocol.
*Sequential testing is unnecessary; the first test alone achieves adequate PPV*
- Given a prevalence of 0.01% and 90% specificity, the **first test** alone would yield a massive amount of false positives, resulting in a very low PPV (~0.09%).
- A **confirmatory test** is clinically and ethically necessary to avoid wrongly diagnosing thousands of healthy individuals with a **rare genetic disorder**.
Question 2: A hospital system is implementing a sepsis screening algorithm using clinical criteria with sensitivity of 92% and specificity of 75%. False positives result in unnecessary antibiotics, cultures, and ICU evaluations costing $3,000 per case. Missing true sepsis cases (false negatives) results in average increased mortality and morbidity costs of $50,000 per case. Hospital sepsis prevalence is 8%. Evaluate the optimal threshold adjustment strategy.
A. Maintain current threshold as it balances sensitivity and specificity equally
B. Implement risk stratification with different thresholds for different populations
C. Abandon screening due to unacceptable false positive rate
D. Increase threshold to improve specificity and reduce costs from false positives
E. Decrease threshold to improve sensitivity despite more false positives (Correct Answer)
Explanation: ***Decrease threshold to improve sensitivity despite more false positives***
- In sepsis screening, the **cost of a false negative** ($50,000) is nearly 17 times higher than the **cost of a false positive** ($3,000), necessitating a strategy that prioritizes **sensitivity** to minimize missed cases.
- Lowering the threshold further ensures fewer high-cost **mortality and morbidity** events occur, which is the most economically and clinically sound approach given the significant **weighted cost** of missing a diagnosis.
*Increase threshold to improve specificity and reduce costs from false positives*
- Increasing the threshold would increase the number of **false negatives**, leading to massive financial losses due to the $50,000 cost per missed **sepsis case**.
- While it reduces the $3,000 expense of unnecessary **antibiotics and cultures**, the savings are mathematically dwarfed by the increased costs of untreated sepsis.
*Maintain current threshold as it balances sensitivity and specificity equally*
- A balanced threshold is inappropriate when the **consequences of error types** are highly asymmetrical; the algorithm should favor the side with the more severe outcome.
- Simply balancing **sensitivity and specificity** fails to account for the 8% **prevalence** and the extreme disparity in costs between false positives and false negatives.
*Implement risk stratification with different thresholds for different populations*
- While risk stratification is useful, it does not address the fundamental need to minimize **false negatives** across the entire 8% prevalence population.
- This approach adds **operational complexity** without necessarily solving the primary economic imbalance between **screening costs** and mortality costs.
*Abandon screening due to unacceptable false positive rate*
- Abandoning screening would lead to an even higher rate of **missed sepsis cases**, resulting in catastrophic clinical outcomes and **increased hospital liability**.
- The current 75% **specificity** is acceptable because the clinical priority in sepsis is **early detection** to prevent rapid physiological deterioration.
Question 3: A 58-year-old man with chronic cough undergoes evaluation for tuberculosis. A tuberculin skin test (TST) is positive (15mm induration). TST has sensitivity of 80% and specificity of 95% in immunocompetent adults. However, he received BCG vaccination as a child in Asia. Local TB prevalence is 0.5%, but his occupational exposure increases his pre-test probability to 10%. Evaluate the most appropriate interpretation and management approach.
A. Calculate post-test probability and obtain interferon-gamma release assay (IGRA) (Correct Answer)
B. Repeat TST in 2 weeks to confirm
C. Treat empirically regardless of test characteristics
D. Positive test confirms TB; start treatment immediately
E. False positive due to BCG; no further testing needed
Explanation: ***Calculate post-test probability and obtain interferon-gamma release assay (IGRA)***
- In individuals previously vaccinated with **BCG**, the **Tuberculin Skin Test (TST)** can yield **false positives** because the test cross-reacts with BCG antigens, whereas **IGRA** is more specific.
- Clinical decision-making requires integrating **pre-test probability** (10% in this case) with test characteristics to determine **post-test probability** before starting long-term therapy.
*Positive test confirms TB; start treatment immediately*
- A positive **TST** in a patient with a **BCG vaccination** history does not automatically confirm infection; it lacks the specificity to distinguish between vaccination and actual **Mycobacterium tuberculosis** infection.
- Starting **antitubercular therapy** immediately without ruling out a false positive or assessing for **active versus latent disease** violates standard diagnostic protocols.
*False positive due to BCG; no further testing needed*
- While **BCG** causes false positives, the patient’s **occupational exposure** and a significant **15mm induration** make infection plausible; dismissing the result is unsafe.
- High-risk individuals require definitive testing, usually via **IGRA**, to ensure **latent tuberculosis infection (LTBI)** is not overlooked.
*Repeat TST in 2 weeks to confirm*
- Repeating a **TST** within a short window can lead to the **booster effect**, where the second test appears positive due to immunological memory rather than new infection.
- Re-testing with the same diagnostic tool does not solve the underlying issue of **BCG cross-reactivity**; a different, more specific test is required.
*Treat empirically regardless of test characteristics*
- Empirical treatment ignores the potential for **medication toxicity** (e.g., hepatotoxicity from Isoniazid) in a patient who might not actually have **LTBI**.
- Evidence-based medicine requires utilizing **sensitivity, specificity, and prevalence** to justify treatment, especially when more specific tests like **IGRA** are available.
Question 4: A research team develops a novel biomarker for early Alzheimer's disease. In their validation study of 500 patients with confirmed Alzheimer's and 500 age-matched controls, the biomarker is positive in 450 Alzheimer's patients and 50 controls. They plan to use this test in a memory clinic where 30% of patients have Alzheimer's. Analyze how the test performance will differ in the clinical setting compared to the validation study.
A. Sensitivity will increase but specificity will decrease in clinical use
B. Sensitivity and specificity will remain the same; PPV and NPV will remain the same
C. Sensitivity and specificity will change; PPV and NPV will remain the same
D. Sensitivity and specificity will remain the same; PPV will decrease and NPV will increase (Correct Answer)
E. All values will remain exactly the same in clinical practice
Explanation: ***Sensitivity and specificity will remain the same; PPV will decrease and NPV will increase***
- **Sensitivity** and **specificity** are intrinsic properties of a diagnostic test and do not change with the **prevalence** of the disease in different populations.
- **Positive Predictive Value (PPV)** is directly proportional to prevalence, while **Negative Predictive Value (NPV)** is inversely proportional; therefore, a drop in prevalence from 50% to 30% decreases the PPV and increases the NPV.
*Sensitivity and specificity will remain the same; PPV and NPV will remain the same*
- While **sensitivity** and **specificity** are stable, **predictive values** are population-dependent and must change if the disease prevalence changes.
- This option incorrectly assumes that **predictive values** are fixed characteristics of the test itself rather than the population.
*Sensitivity and specificity will change; PPV and NPV will remain the same*
- **Sensitivity** and **specificity** are fixed parameters of the test's performance against a **gold standard** and do not shift based on how many people have the disease.
- This incorrectly suggests that **prevalence** affects the test's ability to detect the condition in a single sick individual or rule it out in a healthy one.
*All values will remain exactly the same in clinical practice*
- The **validation study** carries a 50% prevalence (500 cases/1000 total), which is significantly higher than the 30% prevalence in the **memory clinic**.
- Any change in **prevalence** necessitates a recalculation and subsequent change in both **PPV** and **NPV**.
*Sensitivity will increase but specificity will decrease in clinical use*
- Changes in **sensitivity** and **specificity** only occur if the **cut-off point** for a positive test result is adjusted, not by changing the patient population.
- Clinical use in a lower-prevalence setting does not fundamentally change the **biomarker's** biological accuracy in identifying **true positives** or **true negatives**.
Question 5: A 35-year-old woman presents with fatigue and is found to have a positive antinuclear antibody (ANA) test. The test has sensitivity of 95% and specificity of 85% for systemic lupus erythematosus (SLE). She has no other symptoms or physical findings suggestive of SLE. The prevalence of SLE in asymptomatic women her age is 0.1%. Analyze the significance of her positive test result.
A. The test result is equally likely to be true or false positive
B. She most likely has SLE and needs immediate immunosuppressive therapy
C. The positive test is most likely a false positive given low pre-test probability (Correct Answer)
D. The high sensitivity confirms SLE diagnosis
E. She needs repeated ANA testing to confirm the diagnosis
Explanation: ***The positive test is most likely a false positive given low pre-test probability***
- Despite a high **sensitivity** (95%), the extremely low **prevalence** (0.1%) means the **Positive Predictive Value (PPV)** is very low (less than 1%).
- In asymptomatic patients, a positive **ANA test** is much more likely to be a **false positive** than a true indicator of **Systemic Lupus Erythematosus (SLE)**.
*She most likely has SLE and needs immediate immunosuppressive therapy*
- **Immunosuppressive therapy** is never started based on a single laboratory marker without **clinical symptoms** or evidence of organ involvement.
- Most asymptomatic individuals with a positive **ANA** never develop an **autoimmune disease**.
*The high sensitivity confirms SLE diagnosis*
- **Sensitivity** measures how well a test identifies true cases; it does not confirm a diagnosis when the **pre-test probability** is low.
- The **SnNout** mnemonic applies: a highly sensitive test is best for **ruling out** a disease when the result is negative.
*She needs repeated ANA testing to confirm the diagnosis*
- Repeating the same test in an asymptomatic patient does not improve its **Positive Predictive Value** or clinical utility.
- Confirmation of **SLE** relies on **clinical criteria** and more specific tests like **anti-dsDNA** or **anti-Smith**, rather than repeat screening.
*The test result is equally likely to be true or false positive*
- Because the **prevalence** is so low (0.1%), the number of **false positives** (15% of the 99.9% healthy population) far outweighs the **true positives**.
- The ratio of false positives to true positives is approximately **150:1**, meaning it is vastly more likely to be a false positive result.
Question 6: A public health department is comparing two screening tests for colorectal cancer. Test A has sensitivity 85% and specificity 90%. Test B has sensitivity 70% and specificity 98%. The department must screen a population with 2% disease prevalence and has limited resources for colonoscopy follow-up. Analyze which test would be more appropriate for this screening program.
A. Test A because it has better overall accuracy
B. Test B because specificity matters more than sensitivity in screening
C. Either test since both have acceptable characteristics
D. Test B because higher specificity reduces false positives and colonoscopy burden (Correct Answer)
E. Test A because higher sensitivity detects more cancers
Explanation: ***Test B because higher specificity reduces false positives and colonoscopy burden***
- In a low **prevalence** population (2%), a test with high **specificity** is preferred to minimize the number of **false positives**, which reduces the burden on limited **colonoscopy** resources.
- Test B's higher specificity matches the site's resource constraints by ensuring a higher **Positive Predictive Value (PPV)**, meaning fewer healthy patients receive invasive follow-up.
*Test A because higher sensitivity detects more cancers*
- Although higher **sensitivity** (85%) catches more cases, the lower **specificity** (90%) creates a high volume of **false positives** in low prevalence settings.
- This would lead to a significant waste of **limited medical resources** and unnecessary diagnostic risks for many patients.
*Test A because it has better overall accuracy*
- **Accuracy** can be misleading in low prevalence populations and does not account for the specific **resource constraints** mentioned in the scenario.
- Effective screening programs prioritize the metric that minimizes the most costly or risky secondary outcome, which here is the unnecessary **colonoscopy**.
*Test B because specificity matters more than sensitivity in screening*
- This is a flawed generalization; **sensitivity** is often the priority in screening for highly infectious or fatal but treatable diseases to avoid **false negatives**.
- Test B is chosen here specifically due to the combination of **low disease prevalence** and **limited follow-up resources**, not a universal rule.
*Either test since both have acceptable characteristics*
- The choice between screening tests must be tailored to **resource availability** and the **predictive value** derived from the population's **prevalence**.
- Selecting Test A over Test B would likely lead to a system failure due to the **over-utilization** of colonoscopy suites by false-positive patients.
Question 7: A 62-year-old diabetic man undergoes screening for peripheral artery disease using ankle-brachial index (ABI). His ABI is 0.85 (normal >0.90). Studies show ABI has sensitivity of 75% and specificity of 95% for detecting significant PAD. Given his diabetes and symptoms of claudication, the pre-test probability is estimated at 40%. Apply these test characteristics to determine the most appropriate next step.
A. Calculate post-test probability and consider further vascular studies (Correct Answer)
B. Repeat ABI testing to confirm the result
C. Ignore test result and treat based on symptoms alone
D. Proceed directly to revascularization based on positive test
E. Reassure patient that PAD is ruled out given normal specificity
Explanation: ***Calculate post-test probability and consider further vascular studies***
- With a **pre-test probability** of 40% and a sensitivity of 75%, an ABI of 0.85 (positive test) significantly increases the **post-test probability** of PAD using Bayes' Theorem.
- The calculated **Positive Predictive Value (PPV)** in this scenario is High (~89%), confirming that further vascular evaluation (like Duplex Ultrasound) or targeted medical management is necessary.
*Reassure patient that PAD is ruled out given normal specificity*
- Specificity helps rule **in** a disease when the test is positive (**SpPIn**); it does not rule out disease, which is the role of sensitivity.
- The test was actually **positive** (0.85 is < 0.90), so the high specificity actually supports the presence of the disease rather than ruling it out.
*Proceed directly to revascularization based on positive test*
- **Revascularization** is a clinical decision based on the severity of symptoms and anatomic feasibility, not solely on an **ABI value** of 0.85.
- Initial management for PAD typically involves **medical optimization** (antiplatelets, statins) and supervised exercise before considering invasive procedures.
*Repeat ABI testing to confirm the result*
- Repeating a test with the same **sensitivity and specificity** does not change the diagnostic yield unless there was a suspected technical error during the first measurement.
- In a **diabetic patient**, ABI can sometimes be falsely elevated due to **Monckeberg medial sclerosis**, but an already low value is clinically significant and requires action, not repetition.
*Ignore test result and treat based on symptoms alone*
- Ignoring objective data like an **ABI** is inappropriate in evidence-based medicine, as the ABI provides a baseline for **disease progression** and cardiovascular risk.
- While symptoms are important, the **ABI value** helps categorize the severity of PAD and guides the intensity of the **diagnostic workup**.
Question 8: A hospital implements a rapid HIV test with sensitivity of 99% and specificity of 98% in their emergency department. A 28-year-old man with no known risk factors presents after a needlestick injury and tests positive. The prevalence of HIV in the general population presenting to this ED is 0.5%. What is the approximate positive predictive value of his test result?
A. 20% (Correct Answer)
B. 50%
C. 99%
D. 98%
E. 75%
Explanation: ***20%***
- The **Positive Predictive Value (PPV)** is highly dependent on the **prevalence** of the disease; in a low-prevalence population (0.5%), a positive test result has a high probability of being a **false positive**.
- Using the formula **P(True Positive) / [P(True Positive) + P(False Positive)]**, the calculation is (0.005 × 0.99) / [(0.005 × 0.99) + (0.02 × 0.995)], which results in approximately **19.9% or 20%**.
*50%*
- A 50% PPV would only occur if the **prevalence** were higher or the **false positive rate** (1 - specificity) were exactly equal to the prevalence.
- In this case, the **false positive rate (2%)** is four times higher than the **disease prevalence (0.5%)**, making a 50% PPV mathematically incorrect.
*75%*
- This value overestimates the probability because it fails to account for the impact of **low disease prevalence** on the Bayesian calculation.
- To achieve a PPV of 75% with these test parameters, the **prevalence** of HIV in the population would need to be significantly higher than 0.5%.
*98%*
- This value represents the **specificity** of the test, which is the ability to correctly identify those **without the disease**.
- **Specificity** is an intrinsic property of the test and does not change with prevalence, whereas **PPV** is extrinsic and changes based on the population tested.
*99%*
- This value represents the **sensitivity** of the test, which measures the proportion of **true positives** correctly identified among those who actually have the disease.
- Sensitivity does not account for the **false positives** generated when testing a large number of healthy individuals in a low-prevalence setting.
Question 9: A 45-year-old woman undergoes screening mammography. The radiologist reports that the test has a specificity of 95%. In a population where the prevalence of breast cancer is 1%, what does this specificity value primarily tell you about the test's performance?
A. 95% of women with breast cancer will test positive
B. 95% of women without breast cancer will test negative (Correct Answer)
C. 95% of all test results will be accurate
D. The test will miss 5% of breast cancers
E. 95% of positive tests indicate breast cancer
Explanation: ***95% of women without breast cancer will test negative***
- **Specificity** is the proportion of people **without the disease** who are correctly identified by the test as being disease-free (**true negatives**).
- A value of 95% specificity means that among women who truly do not have breast cancer, 95% will receive a **negative mammography result**.
*95% of women with breast cancer will test positive*
- This statement describes **sensitivity**, which measures the test's ability to correctly identify individuals who **actually have the disease**.
- High sensitivity is essential for **screening tests** to ensure that as few cases as possible are missed.
*95% of positive tests indicate breast cancer*
- This refers to the **Positive Predictive Value (PPV)**, which is the probability that a person with a positive test actually has the disease.
- **PPV** is significantly affected by **prevalence**; in a low-prevalence population (1%), a 95% specificity still results in many false positives, lowering the PPV.
*The test will miss 5% of breast cancers*
- This refers to the **False Negative Rate**, which is calculated as **1 minus sensitivity**, not specificity.
- The false negative rate indicates the proportion of diseased individuals who are incorrectly told they are healthy.
*95% of all test results will be accurate*
- This refers to **Overall Accuracy**, which accounts for both true positives and true negatives out of the total population.
- Accuracy is a weighted average of sensitivity and specificity and is heavily influenced by the **prevalence** of the condition.
Question 10: A new screening test for pancreatic cancer is being evaluated in a population of 1,000 patients. Of these, 100 patients have pancreatic cancer confirmed by biopsy. The screening test is positive in 90 of the patients with cancer and positive in 180 of the patients without cancer. What is the sensitivity of this screening test?
A. 50%
B. 90% (Correct Answer)
C. 10%
D. 33%
E. 80%
Explanation: ***90%***
- **Sensitivity** is the ability of a test to correctly identify patients with the disease, calculated as **True Positives (TP)** divided by the sum of **True Positives + False Negatives (FN)**.
- Here, **90 patients** with cancer tested positive out of a total of **100 patients with the disease**, resulting in a sensitivity of 90/100 or **90%**.
*50%*
- This value is an incorrect calculation and does not reflect any standard epidemiological measure based on the provided data.
- It does not represent **Sensitivity**, **Specificity**, or **Predictive Values** for this specific patient population.
*80%*
- This value represents the **Specificity**, which is calculated as **True Negatives (720)** divided by the **Total without disease (900)**.
- **Specificity** measures the test's ability to correctly identify those who truly **do not have the disease**.
*33%*
- This value represents the **Positive Predictive Value (PPV)**, calculated as **True Positives (90)** divided by **Total Positives (90 + 180 = 270)**.
- **PPV** signifies the probability that a person actually has pancreatic cancer given that their **screening test is positive**.
*10%*
- This value represents the **False Negative Rate**, which is the proportion of diseased individuals who were incorrectly identified as healthy.
- It is calculated as **1 minus Sensitivity** (100% - 90%), signifying the **10 cancer patients** who were missed by the test.
